Locally Advanced Pancreatic Cancer: A Review

Seminars in Oncology

Volumn 34, Issue 4, 2007, Pages 327-334

  Russo, Suzanne ^a   Butler, Jerome ^b   Ove, Roger ^a   Blackstock, A William ^b  

^a Baptist Centers for Cancer Care Stem Cell Transplant Program   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CAPECITABINE; CETUXIMAB; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN; PACLITAXEL; STREPTOZOCIN; TRASTUZUMAB;

ADVANCED CANCER; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DRUG DOSE ESCALATION; DUODENUM ULCER; HUMAN; METASTASIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 34547414527     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.05.007     Document Type: Review

References (80)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Evans D., Abbruzzese J., and Willett C. Cancer of the Pancreas (2001), Lippincott Williams & Wilkins, Philadelphia
3. Americna Joint Committee on Cancer. Exocrine pancreas, in Cancer Staging Manual (2002), Springer, New York 157-164
4. Fuhrman G.M., Charnsangavej C., Abbruzzese J.L., et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 167 (1994) 104-111
5. Diehl S.J., Lehmann K.J., Sadick M., et al. Pancreatic cancer: Value of dual-phase helical CT in assessing resectability. Radiology 206 (1998) 373-378
6. Lu D.S., Reber H.A., Krasny R.M., et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 168 (1997) 1439-1443
7. Ichikawa T., Haradome H., Hachiya J., et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 202 (1997) 655-662
8. Sheridan M.B., Ward J., Guthrie J.A., et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: A comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol 173 (1999) 583-590
9. Schwarz M., Pauls S., Sokiranski R., et al. Is a preoperative multidiagnostic approach to predict surgical resectability of periampullary tumors still effective?. Am J Surg 182 (2001) 243-249
10. Eloubeidi M.A., Jhala D., Chhieng D.C., et al. Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer 99 (2003) 285-292
11. Varadarajulu S., and Eloubeidi M.A. The role of endoscopic ultrasonography in the evaluation of pancreatico-biliary cancer. Gastrointest Endosc Clin N Am 15 (2005) 497-511
12. Orlando L.A., Kulasingam S.L., and Matchar D.B. Meta-analysis: The detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 20 (2004) 1063-1070
13. Stefanidis D., Grove K.D., Schwesinger W.H., et al. The current role of staging laparoscopy for adenocarcinoma of the pancreas: A review. Ann Oncol 17 (2006) 189-199
14. Jimenez R.E., Warshaw A.L., Rattner D.W., et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 135 (2000) 409-414
15. Nieveen van Dijkum E.J., de Wit L.T., van Delden O.M., et al. Staging laparoscopy and laparoscopic ultrasonography in more than 400 patients with upper gastrointestinal carcinoma. J Am Coll Surg 189 (1999) 459-465
16. Minsky B.D., Hilaris B., and Fuks Z. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage 3 (1988) 199-205
17. Roldan G.E., Gunderson L.L., Nagorney D.M., et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61 (1988) 1110-1116
18. Moertel C.G., Childs Jr. D.S., Reitemeier R.J., et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2 (1969) 865-867
19. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48 (1981) 1705-1710
20. Gastrointestinal Tumor Study Group. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56 (1985) 2563-2568
21. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: A comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80 (1988) 751-755
22. Klassen D., MacIntyre J., GE C., et al., An Eastern Cooperative Oncology Group study. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-. J Clin Oncol 3 (1985) 373-378
23. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331 (1994) 502-507
24. Whittington R., Neuberg D., Tester W.J., et al. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I Eastern Cooperative Oncology Group trial. J Clin Oncol 13 (1995) 227-232
25. Poen J.C., Collins H.L., Niederhuber J.E., et al. Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Int J Radiat Oncol Biol Phys 40 (1998) 93-99
26. Ben-Josef E., Shields A.F., Vaishampayan U., et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59 (2004) 454-459
27. Saif M.W., Eloubeidi M.A., Russo S., et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of genes related to outcome. J Clin Oncol 23 (2005) 8679-8687
28. Schneider B.J., Ben-Josef E., McGinn C.J., et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1325-1330
29. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15 (1997) 2403-2413
30. Fields M.T., Eisbruch A., Normolle D., et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 47 (2000) 785-791
31. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34 (1996) 867-872
32. Milas L., Fujii T., Hunter N., et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59 (1999) 107-114
33. Poggi M.M., Kroog G.S., Russo A., et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54 (2002) 670-676
34. Ikeda M., Okada S., Tokuuye K., et al. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86 (2002) 1551-1554
35. Blackstock A.W., Bernard S.A., Richards F., et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17 (1999) 2208-2212
36. Pipas J.M., Mitchell S.E., Barth Jr. R.J., et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50 (2001) 1317-1322
37. Blackstock A.W., Tepper J.E., Niedwiecki D., et al. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34 (2003) 107-116
38. Mishra G., Butler J., Ho C., et al. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28 (2005) 345-350
39. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19 (2001) 4202-4208
40. Crane C.H., Janjan N.A., Evans D.B., et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29 (2001) 9-18
41. Wolff R.A., Evans D.B., Gravel D.M., et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7 (2001) 2246-2253
42. Okusaka T., Ito Y., Ueno H., et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 91 (2004) 673-677
43. Epelbaum R., Rosenblatt E., Nasrallah S., et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81 (2002) 138-143
44. Crane C.H., Abbruzzese J.L., Evans D.B., et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys 52 (2002) 1293-1302
45. Li C.P., Chao Y., Chi K.H., et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57 (2003) 98-104
46. Talamonti M.S., Catalano P.J., Vaughn D.J., et al. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 18 (2000) 3384-3389
47. Willett C.G., Czito B.G., Bendell J.C., et al. Locally advanced pancreatic cancer. J Clin Oncol 23 (2005) 4538-4544
48. Safran H., Dipetrillo T., Iannitti D., et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A phase I trial. Int J Radiat Oncol Biol Phys 54 (2002) 137-141
49. Rich T., Harris J., Abrams R., et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27 (2004) 51-56
50. Ashamalla H., Zaki B., Mokhtar B., et al. Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 55 (2003) 679-687
51. Viret F., Ychou M., Goncalves A., et al. Docetaxel and radiotherapy and pancreatic cancer. Pancreas 27 (2003) 214-219
52. Shipley W.U., Nardi G.L., Cohen A.M., et al. Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: A comparative study to surgical resection. Cancer 45 (1980) 709-714
53. Syed A.M., Puthawala A.A., and Neblett D.L. Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer 52 (1983) 808-813
54. Shipley W.U., Wood W.C., Tepper J.E., et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg 200 (1984) 289-296
55. Wood W.C., Shipley W.U., Gunderson L.L., et al. Intraoperative irradiation for unresectable pancreatic carcinoma. Cancer 49 (1982) 1272-1275
56. Tepper J.E., Shipley W.U., Warshaw A.L., et al. The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. J Clin Oncol 5 (1987) 579-584
57. Garton G.R., Gunderson L.L., Nagorney D.M., et al. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 27 (1993) 1153-1157
58. Sindelar W.F., and Kinsella T.J. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 10 suppl 4 (1999) 226-230
59. Tepper J.E., Noyes D., Krall J.M., et al., Radiation Therapy Oncology Group. Intraoperative radiation therapy of pancreatic carcinoma: A report of RTOG-8505. Int J Radiat Oncol Biol Phys 21 (1991) 1145-1149
60. Willett C.G., Del Castillo C.F., Shih H.A., et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 241 (2005) 295-299
61. 125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree. Cancer 58 (1986) 2185-2195
62. Mohiuddin M., Cantor R.J., Biermann W., et al. Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 14 (1988) 79-84
63. Peretz T., Nori D., Hilaris B., et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys 17 (1989) 931-935
64. Smith F.P., Schein P.S., Macdonald J.S., et al. Fast neutron irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 7 (1981) 1527-1531
65. Al-Abdulla A.S., Hussey D.H., Olson M.H., et al. Experience with fast neutron therapy for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 7 (1981) 165-172
66. Cohen L., Woodruff K.H., Hendrickson F.R., et al. Response of pancreatic cancer to local irradiation with high-energy neutrons. Cancer 56 (1985) 1235-1241
67. Thomas F.J., Krall J., Hendrickson F., et al. Evaluation of neutron irradiation of pancreatic cancer. Results of a randomized Radiation Therapy Oncology Group clinical trial. Am J Clin Oncol 12 (1989) 283-289
68. Linstadt D., Quivey J.M., Castro J.R., et al. Comparison of helium-ion radiation therapy and split-course megavoltage irradiation for unresectable adenocarcinoma of the pancreas. Final report of a Northern California Oncology Group randomized prospective clinical trial. Radiology 168 (1988) 261-264
69. Crane C.H., Antolak J.A., Rosen I.I., et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30 (2001) 123-132
70. Milano M.T., Chmura S.J., Garofalo M.C., et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59 (2004) 445-453
71. Landry J.C., Yang G.Y., Ting J.Y., et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): Employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim 27 (2002) 121-129
72. Koong A.C., Christofferson E., Le Q.T., et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63 (2005) 320-323
73. Hoyer M., Roed H., Sengelov L., et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76 (2005) 48-53
74. Crane C., Ellis L., Abbruzzese J., et al. Phase I trial of bevucizumab (BV) with concurrent radiotherapy (RT) and capecitabine (CAP) in locally advanced pancreatic adenocarcinoma (PA). Proc Am Soc Clin Oncol 23 (2005) 316S (abstr)
75. Xiong H.Q., and Abbruzzese J.L. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29 (2002) 31-37
76. Abbruzzese J., Rosenberg A., Xiong Q., et al. Phase II study of an anti-epidermal growth factor receptor cetuximab (IM-C225) in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 20 (2001) 130a (abstr)
77. Safron H., Ramanathan R., Schwartz J., et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Am Soc Clin Oncol 20 (2001) 130 (abstr)
78. Moore M, Goldstein D, Hamm J, et al: Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). ASCO Gastrointestinal Cancer Symposium. Miami, FL, January 27-29, 2005 (abstr 77)
79. Kormansky J, O'Reilly E, Minsky B, et al: A phase I trial of erlotinib, gemcitabine and radiation for patients with locally-advanced, unresectable pancreatic cancer. ASCO Gastrointestinal Cancer Symposium. Miami, FL, January 27-29, 2005 (abstr 133)
80. Iannitti D., Dipetrillo T., Akerman P., et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: A phase I study. Am J Clin Oncol 28 (2005) 570-575